Septic ShockNCT06363149
Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients
An observational study of Septic Shock and Disseminated Intravascular Coagulation, run by Sanjay Gandhi Postgraduate Institute of Medical Sciences at 1 site in India.
Trial summary
Septic shock is common complication in patients with critical illnesses, with higher incidence in low and medium income countries like ours. Disseminated intravascular coagulation (DIC) is also common in patients presenting to intensive care units. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Septic Shock, Disseminated Intravascular Coagulation
- How many people
- 60 participants
- Where
- 1 siteIndia
- Study dates
- 12 Apr 2024to 25 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered.
Who may be able to join
- Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered.
Who cannot join
- Patient having septic shock duration either less than 12 hours or more than 24 hours at the time of the inclusion
- Age less than 18 years or more than 65 years
- Expected survival less than 72 hours
- Caregiver refused for the consent to participate in the study
Trial locations and contacts
1 site in 1 country.
India1 site
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, 226014
About this study
Official title: Effect of Disseminated Intravascular Coagulation (DIC) Score Changes on Organ Dysfunction in Septic Shock Patients
Septic shock is common complication in patients with critical illnesses, with higher incidence in low and medium income countries like ours. Disseminated intravascular coagulation (DIC) is also common in patients presenting to intensive care units. Further DIC is common coexisting condition seen in many patients presenting with sepsis and septic shock.
Both DIC and septic shock individually are associated with very high mortality and morbidity and coexistence of both increase risk manifold. Organ dysfunction is a complication of both septic shock and DIC individually and in presence of coexistence risk further multiply. DIC scoring of every patient at risk as in patients presenting with septic shock help us to predict about patients having more chances to convert to overt DIC.
Understanding effects of DIC on organ dysfunction in septic shock patients can help to prognosticate and guide towards early intervention. Also, there is paucity of literature on effect of DIC score changes on organ dysfunction in patients with septic shock.
Read the detailed description
Background and rationale for the study Septic shock patients and DIC commonly coexist and progression to overt DIC is serial process. Sepsis and septic shock condition is a prevalent condition as studied by Stephen et al especially in low medium income countries with incidence of 31.5 million per year. Divatia JV et al found incidence of severe sepsis and septic shock 28.3% in study covering different ICUs in India. Rhee C et al found incidence of severe sepsis and septic shock as high as 52.8%. Marx,G., et al observed incidence of septic shock in German ICUs to be 12.6 % whereas Mulatu HA et al found it to be 26.5% in African ICUs.
Also, septic shock has very high mortality rates. In India, Divatia JV et al observed that mortality in septic shock patients was 53.4 % and Chatterjee et al observed it to be 62.8%. Mortality rate according to different geographical locations have variations but still consistently high: 22.8% mortality in Greece ICUs, 79% in Turkish ICUs observed by Baykara et al in Japan 27%, in Taiwan 43.8%, in China 51.9 %.
Disseminated intravascular coagulation (DIC) is prevalent entity in sepsis/septic shock patients as observed in different studies: Ko BS et al observed prevalence to be 17.6%, Dhainut J.F et al found it to be 28.9%, Saito et al in Japan to be 29% and J Kienast et al in Germany observed it to be 40.7%.
DIC itself has high mortality: 29.1%, 40.7%, 50% and as high as 56%. Mortality rates further increases when DIC co exists with severe sepsis as seen 67.6% by Ogura H et al, 44.6% vs. 55.3 % without and with DIC respectively seen by Hayakawa et al, 11.7% vs. 54.1% without and with DIC respectively seen by Solanki D et al .
Septic shock patients are at high risk of develop multiple organ dysfunction (MODS). In fact, both DIC score and organ dysfunction were found increased in patients with septic shock as compared to patients without septic shock so the resultant higher mortality and MODS. Studies also found mortality risk further increases in septic shock patients with the presence of DIC.
Methodology Study design: This prospective observational study will be conducted at the Department of Critical Care Medicine in collaboration with the Department of Haematology, SGPGIMS, Lucknow after the approval from the Institutional Ethics Committee (IEC) Study protocol: During the study period, all adult ICU participants with the diagnosis of septic shock will be considered, as per inclusion and exclusion criteria, DIC scores and SOFA scores will be calculated and followed-up for the 14 days.
Definition and scores: Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Participants with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level greater than 2mmol/L in the absence of hypovolemia (Sepsis -3 recommendations). DIC score for overt and non-overt DIC will be used as per International Society on Thrombosis and Haemostasis. (ISTH) Sample collection for DIC score calculation Blood samples will be collected as below Baseline sampling : At inclusion Second sampling : At 72 hours ±12 hours Third sampling : After 72 hours (±12 hours) of second sampling. Data collections: Demographic and relevant clinical characteristics of included participants will be collected on structured case report form.
Sample size and statistical analysis: Based on the study conducted by the H Ogura et al. (2014), SOFA score was during the day 1 (10.7±3.8) to day 4 (8.9±5.0) [Change in score: Cohen d effect size =0.398). At minimum two-sided 95% confidence and 80% power of the study, minimum estimated sample size for the study is 52. Finally minimum 60 participants to be enrolled in the study. Sample size was estimated using software G*power version 3.1.9.7. Descriptive statistics of the continuous variables will be presented as mean ± SD / Median (IQR) whereas categorical variables in Frequency (%). To compare the observations between baseline to follow-up data (quantitative variable), with the outcomes, two-way repeated measures ANOVA will be used. One way Analysis of covariance to be used to compare the post observations into outcomes after the adjusting the baseline measurements. Change in the SOFA score with change in the DIC score to be compared using spearman rank correlation coefficient. Decision trees analysis including Classification and regression trees to be used to identify the factors and subgroups predicting the outcomes. General linear regression model to be used to identify the factors predicting the change in the SOFA score. A p value < 0.05 to be considered as statistically significant. Statistical analysis to be performed using software "Statistical package for social sciences version 23 (SPSS-23) and MedCalc.
- Keywords
- Critical Illnesses, Multiple Organ Dysfunction Syndrome
- Medical subject headings
- Shock, Septic, Disseminated Intravascular Coagulation, Critical Illness, Multiple Organ Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Septic shock | Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered for inclusion in this observational study.. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of Disseminated Intravascular Coagulation score changes on organ dysfunction in septic shock patients at day 7
Correlation of Disseminated Intravascular Coagulation score (0 to 8, where higher score is severe) and its change with the organ dysfunction measured as Sequential Organ Failure Assessment score (0 to 24, where higher score has worse outcome)
Measured: At day 7 after inclusion
Secondary outcomes (1)
Effect of Disseminated Intravascular Coagulation score changes on organ dysfunction in septic shock patients at day 14
Correlation of Disseminated Intravascular Coagulation score (0 to 8, where higher score is severe) and its change with the organ dysfunction measured as Sequential Organ Failure Assessment score (0 to 24, where higher score has worse outcome)
Measured: At day 14 after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2024
- Study start12 Apr 2024
- Primary completion25 Aug 2025
- Study completion25 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Mohan Gurjar, Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Investigators
- Mohan Gurjar, MD, PDCC, Principal investigator, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)Dinesh Chandra, MD, DM, Principal investigator, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06363149
- Sponsor's protocol ID
- 2024-11-DM-136
- Status last verified
- Jul 2026
- First submitted
- 9 Apr 2024
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Disseminated Intravascular Coagulation (DIC) Score Changes on Organ Dysfunction in Septic Shock Patients
- ClinicalTrials.gov ID
- NCT06363149
- Acronym / sponsor ID
- 2024-11-DM-136
- Keywords
- Critical Illnesses, Multiple Organ Dysfunction Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Sanjay Gandhi Postgraduate Institute of Medical SciencesOther government
- Study start
- 12 Apr 2024 (actual)
- Primary completion
- 25 Aug 2025 (actual)
- Study completion
- 25 Aug 2025 (actual)
- First posted
- 12 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Septic shock is common complication in patients with critical illnesses, with higher incidence in low and medium income countries like ours. Disseminated intravascular coagulation (DIC) is also common in patients presenting to intensive care units. Further DIC is common coexisting condition seen in many patients presenting with sepsis and septic shock.
Both DIC and septic shock individually are associated with very high mortality and morbidity and coexistence of both increase risk manifold. Organ dysfunction is a complication of both septic shock and DIC individually and in presence of coexistence risk further multiply. DIC scoring of every patient at risk as in patients presenting with septic shock help us to predict about patients having more chances to convert to overt DIC.
Understanding effects of DIC on organ dysfunction in septic shock patients can help to prognosticate and guide towards early intervention. Also, there is paucity of literature on effect of DIC score changes on organ dysfunction in patients with septic shock.
Detailed description
Background and rationale for the study Septic shock patients and DIC commonly coexist and progression to overt DIC is serial process. Sepsis and septic shock condition is a prevalent condition as studied by Stephen et al especially in low medium income countries with incidence of 31.5 million per year. Divatia JV et al found incidence of severe sepsis and septic shock 28.3% in study covering different ICUs in India. Rhee C et al found incidence of severe sepsis and septic shock as high as 52.8%. Marx,G., et al observed incidence of septic shock in German ICUs to be 12.6 % whereas Mulatu HA et al found it to be 26.5% in African ICUs.
Also, septic shock has very high mortality rates. In India, Divatia JV et al observed that mortality in septic shock patients was 53.4 % and Chatterjee et al observed it to be 62.8%. Mortality rate according to different geographical locations have variations but still consistently high: 22.8% mortality in Greece ICUs, 79% in Turkish ICUs observed by Baykara et al in Japan 27%, in Taiwan 43.8%, in China 51.9 %.
Disseminated intravascular coagulation (DIC) is prevalent entity in sepsis/septic shock patients as observed in different studies: Ko BS et al observed prevalence to be 17.6%, Dhainut J.F et al found it to be 28.9%, Saito et al in Japan to be 29% and J Kienast et al in Germany observed it to be 40.7%.
DIC itself has high mortality: 29.1%, 40.7%, 50% and as high as 56%. Mortality rates further increases when DIC co exists with severe sepsis as seen 67.6% by Ogura H et al, 44.6% vs. 55.3 % without and with DIC respectively seen by Hayakawa et al, 11.7% vs. 54.1% without and with DIC respectively seen by Solanki D et al .
Septic shock patients are at high risk of develop multiple organ dysfunction (MODS). In fact, both DIC score and organ dysfunction were found increased in patients with septic shock as compared to patients without septic shock so the resultant higher mortality and MODS. Studies also found mortality risk further increases in septic shock patients with the presence of DIC.
Methodology Study design: This prospective observational study will be conducted at the Department of Critical Care Medicine in collaboration with the Department of Haematology, SGPGIMS, Lucknow after the approval from the Institutional Ethics Committee (IEC) Study protocol: During the study period, all adult ICU participants with the diagnosis of septic shock will be considered, as per inclusion and exclusion criteria, DIC scores and SOFA scores will be calculated and followed-up for the 14 days.
Definition and scores: Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Participants with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level greater than 2mmol/L in the absence of hypovolemia (Sepsis -3 recommendations). DIC score for overt and non-overt DIC will be used as per International Society on Thrombosis and Haemostasis. (ISTH) Sample collection for DIC score calculation Blood samples will be collected as below Baseline sampling : At inclusion Second sampling : At 72 hours ±12 hours Third sampling : After 72 hours (±12 hours) of second sampling. Data collections: Demographic and relevant clinical characteristics of included participants will be collected on structured case report form.
Sample size and statistical analysis: Based on the study conducted by the H Ogura et al. (2014), SOFA score was during the day 1 (10.7±3.8) to day 4 (8.9±5.0) [Change in score: Cohen d effect size =0.398). At minimum two-sided 95% confidence and 80% power of the study, minimum estimated sample size for the study is 52. Finally minimum 60 participants to be enrolled in the study. Sample size was estimated using software G*power version 3.1.9.7. Descriptive statistics of the continuous variables will be presented as mean ± SD / Median (IQR) whereas categorical variables in Frequency (%). To compare the observations between baseline to follow-up data (quantitative variable), with the outcomes, two-way repeated measures ANOVA will be used. One way Analysis of covariance to be used to compare the post observations into outcomes after the adjusting the baseline measurements. Change in the SOFA score with change in the DIC score to be compared using spearman rank correlation coefficient. Decision trees analysis including Classification and regression trees to be used to identify the factors and subgroups predicting the outcomes. General linear regression model to be used to identify the factors predicting the change in the SOFA score. A p value < 0.05 to be considered as statistically significant. Statistical analysis to be performed using software "Statistical package for social sciences version 23 (SPSS-23) and MedCalc.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Septic shock | – | –Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered for inclusion in this observational study.. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered.
Key inclusion criteria (1 listed)
- Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered.
Key exclusion criteria (4 listed)
- Patient having septic shock duration either less than 12 hours or more than 24 hours at the time of the inclusion
- Age less than 18 years or more than 65 years
- Expected survival less than 72 hours
- Caregiver refused for the consent to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Effect of Disseminated Intravascular Coagulation score changes on organ dysfunction in septic shock patients at day 7
Time frame: At day 7 after inclusion
Correlation of Disseminated Intravascular Coagulation score (0 to 8, where higher score is severe) and its change with the organ dysfunction measured as Sequential Organ Failure Assessment score (0 to 24, where higher score has worse outcome)
1 secondary outcome
Effect of Disseminated Intravascular Coagulation score changes on organ dysfunction in septic shock patients at day 14
Time frame: At day 14 after inclusion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Septic Shock
RecruitingPhase 3
Systematic Adjunction of Vasopressine in Septic Shock
Septic Shock
Not yet recruitingObservational study
Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational Study
Sepsis
Not yet recruitingObservational study
Neutrophil Activation and NETosis in Sepsis
Sepsis, Septic Shock
Recruiting
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
Septic Shock, Methylene Blue
RecruitingObservational study
CytOSorb TreatMent Of Critically Ill PatientS Registry
Septic Shock, Acute Respiratory Distress Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohan Gurjar, MD, PDCC principal investigator
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
Dinesh Chandra, MD, DM principal investigator
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Septic Shock and Disseminated Intravascular Coagulation, run by Sanjay Gandhi Postgraduate Institute of Medical Sciences at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of Disseminated Intravascular Coagulation score changes on organ dysfunction in septic shock patients at day 7 (time frame: At day 7 after inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026; AzTrials last refreshed its copy on 26 Oct 2026.